Anti-androgen剤の前立腺肥大症にたいする効果の病理組織学的研究 - TSAA-291投与前後の前立腺生検像の比較検討 -

Abstract

TSAA-291, a new synthetic anti-androgen, was administered to 47 patients with benign prostatic hyperplasia for twelve weeks. The dosage per week was 200 mg in 7, 400 mg in 23 and 600 mg in 17 patients. The prostate was biopsied before and after the course of treatment. A committee was formed for histological evaluation of the prostate. Degenerative changes were evaluated according to the scoring method established by the committee. Histological improvement was proved in 43% of the 200 mg group, in 70% of the 400 mg group and 59% of the 600 mg group. The over-all effect was seen in 62%. Six cases which showed marked histological alterations were discussed in detail. Therapeutic effect of TSAA-291 on benign prostatic hyperplasia can be expected according to our pathohistological evaluation which was blindly performed.